# eCardio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ecardio

- Industry: Medical Devices & Equipment
- Headquarters: Houston, US
- Website: www.ecardio.com
- Latest round: Series A (Jul 1, 2009)
- Investors on record: 1

## About

eCardio specializes in cardiac monitoring solutions, focusing on advanced remote ECG devices to support patients and healthcare providers in managing heart health effectively.eCardio is dedicated to providing innovative cardiac monitoring solutions. The company is headquartered in Houston, US, and has undergone significant developments since its inception. In July 2009, Sequoia Capital completed a Series A financing round for eCardio, although the financial terms were not disclosed. The founder's history is not detailed publicly; therefore, further information on prior ventures is not available.eCardio offers advanced cardiac monitoring solutions, notably the BodyGuardian product line, which includes the BodyGuardian MINI and BodyGuardian MINI PLUS. These remote ECG devices are designed for continuous use, enabling patients to collect critical heart data 24/7 while engaging in their daily activities. The products facilitate comprehensive data collection for physicians, aiming to enhance patient outcomes through seamless electronic medical record integrations across various healthcare environments. eCardio serves a diverse clientele of healthcare professionals, hospitals, and clinics primarily in the US and Europe.eCardio operates on a revenue model focused on the sales of its cardiac monitoring devices and related services. Transactions occur through direct sales to healthcare providers and facilities, allowing for partnerships or subscription agreements for ongoing monitoring services. This business structure supports both B2B and direct-to-consumer channels, ensuring that the pricing for products like the BodyGuardian series meets the diverse needs of medical institutions while maintaining operational sustainability.eCardio's strategy for future growth includes the potential development and launch of new cardiac monitoring products, although specific details and release dates are not currently available. The company aims to expand its presence in new geographic markets, specifically targeting regions across the US and Europe. The funding received during the Series A round in July 2009 will support these initiatives, although detailed allocations for future products or market expansion have not been disclosed.

## Funding rounds

- Series A, Jul 1, 2009 — Hong Shan

## Investors

- Hong Shan — Series A